このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Immunovia マネジメント

マネジメント基準チェック /14

Immunovia'sの CEO はJeff Borcherdingで、 Apr2023年に任命され、の在任期間は 1.17年です。は、会社の株式の0.77%を直接所有しており、その価値はSEK 518.70K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と4.1年です。

主要情報

Jeff Borcherding

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.2yrs
CEOの所有権	0.8%
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Jan 18

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Aug 28

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Mar 09

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Feb 03

Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price

Dec 30

Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares

Dec 03

CEO（最高経営責任者

Jeff Borcherding (51 yo)

1.2yrs

在職期間

Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeff Borcherding	Global Chief Executive Officer & President	1.2yrs	データなし	0.77% SEK 616.0k
Karin Liwendahl	Chief Financial Officer	2.2yrs	データなし	データなし
Karl Stone	Chief Operating Officer	1.3yrs	データなし	データなし
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.3yrs	データなし	データなし

1.3yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: IMMNOVの経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Peter Hongaard Andersen	Independent Chairman	4.1yrs	kr475.00k	データなし
Hans Johansson	Independent Director	8.4yrs	kr280.00k	0.10% SEK 81.3k
Margaret Tempero	Member of Medical Advisory Board	8yrs	データなし	データなし
Diane Simeone	Member of Medical Advisory Board	7.9yrs	データなし	データなし
Michael Lofman	Independent Director	1.1yrs	kr175.00k	データなし
Valerie Bogdan-Powers	Independent Director	less than a year	kr16.00k	データなし
Stephen Pereira	Member of Medical Advisory Board	6.9yrs	データなし	データなし
Melissa Farina	Independent Director	less than a year	kr16.00k	データなし
Martin Moller	Independent Director	3.1yrs	kr302.00k	データなし

4.1yrs

平均在職期間

57yo

平均年齢

経験豊富なボード: IMMNOVの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Immunovia マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Full year 2023 earnings released: kr7.95 loss per share (vs kr7.43 loss in FY 2022)

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Third quarter 2023 earnings released: kr0.91 loss per share (vs kr1.01 loss in 3Q 2022)

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Revenue and earnings growth

Immunovia AB (publ) Announces Board Changes

First quarter 2023 earnings released: kr2.28 loss per share (vs kr1.95 loss in 1Q 2022)

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching Immunovia's (STO:IMMNOV) Cash Burn Situation

Forecast to breakeven in 2024

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

We're Keeping An Eye On Immunovia's (STO:IMMNOV) Cash Burn Rate

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Forecast to breakeven in 2024

Price target decreased to kr110

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immunovia AB (Publ) Announces Board Changes

Independent Director recently bought kr186k worth of stock

Price target decreased to kr215

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

Third quarter 2021 earnings released: kr1.60 loss per share (vs kr1.68 loss in 3Q 2020)

Price target increased to kr298

We Think Immunovia (STO:IMMNOV) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Chief Executive Officer recently bought kr676k worth of stock

Price target increased to kr300

Independent Director recently bought kr298k worth of stock

Independent Director has left the company

Independent Director recently bought kr192k worth of stock

First quarter 2021 earnings released: kr1.04 loss per share (vs kr1.41 loss in 1Q 2020)

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

New 90-day high: kr131

What Kind Of Investors Own Most Of Immunovia AB (publ) (STO:IMMNOV)?

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Earnings miss expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

Immunovia's PanFAM Prospective Study Gathers over 3000 Familial Hereditary Pancreatic Cancer Risk Samples and Will Be Analysed in the Second Half of 2021

Here's Why We're Not Too Worried About Immunovia's (STO:IMMNOV) Cash Burn Situation

New 90-day low: kr111

Immunovia AB Announces Results from Study in Their Development Pipeline

Immunovia AB (publ)'s (STO:IMMNOV) Intrinsic Value Is Potentially 72% Above Its Share Price

New 90-day low: kr111

Insider Buying: The Immunovia AB (publ) (STO:IMMNOV) Director Just Bought kr293k Worth Of Shares

マネジメント基準チェック /14